NOVARTIS’ PAY-OUT APPEAL LESS IN DEMAND, FOR NOW (ADD; 8% UPSIDE)
21/12/20 -"2020 ridiculed various market notions, including the long-held principle of defensive investing in turbulent times. Hence, year-to-date, the Pharma sector lost 0.9% in value, which was not far away ..."
Pages
72
Language
English
Published on
21/12/20
You may also be interested by these reports :
14/10/26
Since we last teased Genmab’s (ADD; Denmark) story – a company that specialises in developing antibodies for cancer treatment – in February 2025, the ...
07/10/26
Our estimates are already at the higher end, with our target price significantly benefitting from increased NAV and DCF estimates, as well as a ...
30/09/26
Lundbeck, as per Bloomberg, is pursuing endocrine- and neurology-focused Xeris Biopharma, whose market cap is c.28% of that of Lundbeck. Considering ...
24/09/26
A years/decades long search for revolutionary multi-blockbuster drug(s), a phenomenal run for some years and then concerns sprout around ...